Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.59 |
| ▸ | CALCR | P30988 | 4/20 | 0.58 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.55 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.53 |
| ▸ | CCKBR | P32239 | 2/20 | 0.52 |
| ▸ | GLP1R | P43220 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2448693 | 0.87 | CALCR (0.71) | F2CALCRHCRTR1HCRTR2CCKBR | |
| SCHEMBL31453812 | 0.86 | F2 (0.67) | F2CALCRHCRTR1HCRTR2CCKBR | |
| SCHEMBL31453815 | 0.86 | F2 (0.67) | F2CALCRHCRTR1HCRTR2CCKBR | |
| SCHEMBL30431706 | 0.85 | CALCR (0.66) | F2CALCRHCRTR1HCRTR2CCKBR | |
| SCHEMBL29812479 | 0.85 | CALCR (0.66) | F2CALCRHCRTR1HCRTR2CCKBR | |
| SCHEMBL30974240 | 0.85 | F2 (0.58) | F2CALCRHCRTR1HCRTR2OPRD1 | |
| SCHEMBL29903351 | 0.85 | CALCR (0.71) | F2CALCRHCRTR1HCRTR2CCKBR | |
| SCHEMBL30726594 | 0.84 | CALCR (0.73) | F2CALCRHCRTR1HCRTR2CCKBR | |
| SCHEMBL30974376 | 0.84 | F2 (0.58) | F2CALCRHCRTR1HCRTR2OPRD1 | |
| SCHEMBL29942474 | 0.83 | CALCR (0.68) | F2CALCRHCRTR1HCRTR2CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | F2 2732/4885CALCR 2817/4885HCRTR1 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.